Compare USEG & CLGN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | USEG | CLGN |
|---|---|---|
| Founded | 1966 | 2004 |
| Country | United States | Israel |
| Employees | N/A | N/A |
| Industry | Oil & Gas Production | Industrial Specialties |
| Sector | Energy | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 39.1M | 33.8M |
| IPO Year | N/A | N/A |
| Metric | USEG | CLGN |
|---|---|---|
| Price | $1.06 | $2.06 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 1 | 2 |
| Target Price | $3.50 | ★ $11.50 |
| AVG Volume (30 Days) | ★ 285.1K | 19.4K |
| Earning Date | 11-12-2025 | 11-26-2025 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | ★ $9,484,000.00 | $2,475,000.00 |
| Revenue This Year | N/A | $1,617.28 |
| Revenue Next Year | $57.52 | $83.54 |
| P/E Ratio | N/A | N/A |
| Revenue Growth | N/A | ★ 280.77 |
| 52 Week Low | $0.94 | $1.31 |
| 52 Week High | $6.40 | $4.98 |
| Indicator | USEG | CLGN |
|---|---|---|
| Relative Strength Index (RSI) | 50.79 | 40.59 |
| Support Level | $0.96 | $1.92 |
| Resistance Level | $1.05 | $2.10 |
| Average True Range (ATR) | 0.06 | 0.15 |
| MACD | 0.01 | 0.00 |
| Stochastic Oscillator | 92.30 | 27.27 |
US Energy Corp is an independent energy company. It is focused on the acquisition and development of oil and natural gas-producing properties in the continental United States. It has business properties and operations in the Rockies region (Montana, Wyoming, and North Dakota), the Mid-Continent (Oklahoma, Kansas, and North and East Texas), and the West Texas, South Texas, and Gulf Coast regions. The company generates revenue from its interest in the sales of oil and natural gas production. The group operates in the exploration and production segment of the oil and gas industry, onshore in the United States.
CollPlant Biotechnologies Ltd is a regenerative and aesthetic medicine company focused on 3D bioprinting of tissues and organs and medical aesthetics. Its products are based on its rhCollagen (recombinant human collagen) produced with CollPlant's proprietary plant based genetic engineering technology. These products address indications for the diverse fields of tissue repair, aesthetics, and organ manufacturing. The revenues include income from business collaborators and sales of the BioInk product for the development of 3D bioprinting of organs and tissues, sales of rhCollagen for the medical aesthetics market, and sales in Europe of the products for tendinopathy and wound healing. The company operates in United States, which derives key revenue, Canada, Europe and Other, and Israel.